Clinical

Myasthenia gravis expert James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains the burdens that step therapy places on patients with rare diseases and their providers.

Experts report that among skin diseases, atopic dermatitis has the lowest reported quality of life.

Soyini Hawkins, MD, MPH, FACOG, drives a conversation regarding the impact of race in diagnosing endometriosis.

Early detection of uterine fibroids and endometriosis has been powered by the Affordable Care Act, ultimately improving prognosis for patient outcomes.

Pulmonary arterial hypertension (PAH) is the only major diagnostic indication for transplantation that is not a parenchymal pulmonary process.

Compared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.

A new small case series finds higher rates of symptom flares in individuals who have muscle-specific tyrosine kinase (MuSK)–positive myasthenia gravis (MG) than previous research.

Osimertinib plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) vs osimertinib alone in patients with epidermal growth factor receptor–mutated (EGFRm) advanced non–small cell lung cancer (NSCLC)

Little is known about opioid prescribing patterns in patients with chronic overlapping pain conditions. This study suggests target populations for interventions to manage chronic pain.

Key opinion leaders dive into the use of bispecific treatment options for RRMM.

Various treatment options for patients with relapsed/refractory MM are discussed.

Immune checkpoint inhibitors (ICIs) can increase life expectancy among patients who have non–small cell lung cancer (NSCLC), but they also carry the risk of immune-related adverse events.

Researchers suggest socioeconomic status (SES) be considered in prognostic algorithms going forward.

Adam C. Welch, PharmD, MBA, FAPhA, leads a panel discussion surrounding complications related to RSV infection.

A panel of medical experts discuss the prevalence of RSV in adults.

Budd-Chiari syndrome and myeloproliferative neoplasms (MPNs) are rare, which means available data are limited.

There is a concerted effort to identify biomarkers to understand the risk of progression of diabetic eye disease, but many studies have not been performed in diverse populations, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.

Dr Butrus leads a discussion on the ideal patient population for treating atopic dermatitis with ruxolitinib.

The panelists highlight the treatment nature of ruxolitinib, a JAK inhibitor used to treat atopic dermatitis.

Using a diverse human gut community, researchers investigated how gut microbiota interspecies interactions affected the response of Clostridioides difficile to vancomycin and metronidazole.

The training did not, however, affect postoperative limb skeletal muscle weakness or exercise capacity.

Researchers compared chimeric antigen receptor T-cell therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel.

Patients who have extrinsic (EAD) or intrinsic atopic dermatitis (IAD) serve to benefit equally from dupilumab, even when considering immunoglobulin E levels, which are elevated in EAD but remain normal in IAD.

Medical experts provide insights surrounding efforts to ensure equitable health for women across underserved patient populations.

Derek van Amerongen, MD, MS, leads a panel discussion surrounding disparities currently facing women in health care.

Findings show these drugs were linked with a lower risk of progression to inflammatory arthritis compared with tumor necrosis factor inhibitors, although more research is needed to confirm the finding.

Dr Matous leads a conversation regarding CAR T-cell therapy for treating multiple myeloma.

The panel provides an overview of drug treatment options for patients with RRMM.

No benefit was found in low-risk patients who underwent pelvic lymph node dissection (PLND).

The findings support policies urging vaccination of individuals who have myasthenia gravis (MG).